Biodegradation and biocompatibility of PLA and PLGA microspheres

被引:1728
作者
Anderson, JM [1 ]
Shive, MS [1 ]
机构
[1] CASE WESTERN RESERVE UNIV, DEPT BIOMED ENGN, CLEVELAND, OH 44106 USA
关键词
inflammatory response; foreign body response; macrophages; foreign body giant cells; hydrolytic degradation; therapeutic agent release; in vivo tissue response;
D O I
10.1016/S0169-409X(97)00048-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A fundamental understanding of the in vivo biodegradation phenomenon as well as an appreciation of cellular and tissue responses which determine the biocompatibility of biodegradable PLA and PLGA microspheres are important components in the design and development of biodegradable microspheres containing bioactive agents for therapeutic application. This chapter is a critical review of biodegradation, biocompatibility and tissue/material interactions, and selected examples of PLA and PLGA microsphere controlled release systems. Emphasis is placed on polymer and microsphere characteristics which modulate the degradation behaviour and the foreign body reaction to the microspheres. Selected examples presented in the chapter include microspheres incorporating bone morphogenetic protein (BMP) and leuprorelin acetate as well as applications or interactions with the eye, central nervous system, and lymphoid tissue and their relevance to vaccine development. A subsection on nanoparticles and nanospheres is also included. The chapter emphasizes biodegradation and biocompatibility; bioactive agent release characteristics of various systems have not been included except where significant biodegradation and biocompatibility information have been provided. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:5 / 24
页数:20
相关论文
共 76 条
[1]   PEG-COATED POLY(LACTIC ACID) NANOPARTICLES FOR THE DELIVERY OF HEXADECAFLUORO ZINC PHTHALOCYANINE TO EMT-6 MOUSE MAMMARY-TUMORS [J].
ALLEMANN, E ;
BRASSEUR, N ;
BENREZZAK, O ;
ROUSSEAU, J ;
KUDREVICH, SV ;
BOYLE, RW ;
LEROUX, JC ;
GURNY, R ;
VANLIER, JE .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (05) :382-387
[2]  
ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P173
[3]  
Allemann E, 1996, INT J CANCER, V66, P821, DOI 10.1002/(SICI)1097-0215(19960611)66:6<821::AID-IJC19>3.0.CO
[4]  
2-5
[5]  
ALLEMANN E, 1996, IN PRESS J BIOMED MA
[6]  
Anderson J.M., 1984, HARPER ROW, P248
[7]  
Anderson James M., 1995, P223
[8]  
ANDERSON JM, 1993, CARDIOVASC PATHOL, V2, pS33
[9]  
ANDERSON JM, 1994, EUR J PHARM BIOPHARM, V40, P1
[10]  
Anderson JM, 1994, PROB GEN SURG, V11, P147